GHRL and esophageal cancer: Furthermore, a Japanese prospective, randomized, placebo-controlled study targeting esophageal cancer confirmed that co-administration of intravenous infusions of synthetic human ghrelin (3 μg/kg) twice daily for one week with cisplatin-based neoadjuvant chemotherapy suppressed chemotherapy-induced anorexia, nausea, and vomiting [12].